Roche YTD September 2014 sales Basel, 16 October 2014 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as вЂ�believes’, вЂ�expects’, вЂ�anticipates’, вЂ�projects’, вЂ�intends’, вЂ�should’, вЂ�seeks’, вЂ�estimates’, вЂ�future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 2 3 4 5 6 7 8 9 10 11 pricing and product initiatives of competitors; legislative and regulatory developments and economic conditions; delay or inability in obtaining regulatory approvals or bringing products to market; fluctuations in currency exchange rates and general financial market conditions; uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; increased government pricing pressures; interruptions in production; loss of or inability to obtain adequate protection for intellectual property rights; litigation; loss of key executives or other employees; and adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com All mentioned trademarks are legally protected. 3 Group Severin Schwan Chief Executive Officer 4 Q3 2014: Highlights Growth • Group sales +5%1 as of YTD Sept 2014 driven by HER2 franchise (+21%1), Avastin (+6%1), Actemra (+24%1) and Professional Diagnostics (+8%1) • Group International growth accelerated to +8%1 in Q3 2014 (up from +6%1 in Q2 & +3%1 in Q1) Innovation • ESMO 2014 highlights: new data on Perjeta, Avastin in TML and cobimetinib/Zelboraf in melanoma as well as encouraging updates on cancer immunotherapy • Approvals: Avastin in ovarian cancer (EU), cervical cancer (US); Actemra in early RA (EU); Gazyvaro in CLL (EU) • Filings: Lucentis in diabetic retinopathy (US), Perjeta in neo-adjuvant (EU) Acquisition of InterMune • Tender offer: Successfully completed, closing September 29, 2014 • Financing: Bond issuance successfully completed with USD 5.75bn raised • Esbriet: Approved in the US 1 CER=Constant Exchange Rates 5 YTD Sept 2014: Strong sales growth continues YTD Sept YTD Sept 2014 2013 Pharmaceuticals Division Diagnostics Division Roche Group CER=Constant Exchange Rates Change in % CHFbn CHFbn CHF CER 27.0 27.2 -1 4 7.8 7.7 1 6 34.8 34.9 0 5 6 Roche Group sales: Continued growth for 3yrs 10% 8% 8% 6% 6% 5% 4% 4% 4% 2% 0% 0% 0% -2% 7% 6% 6% 1% 4% 5% 4% 2% -3% -4% -5% -6% Q3 10 Q4 10 Q1 11 Q2 11 Q3 11 Q4 11 All growth rates at Constant Exchange Rates (CER) Q1 12 Q2 12 Q3 12 Q4 12 Q1 13 Q2 13 Q3 13 Q4 13 Q1 14 Q2 14 Q3 14 7 YTD Sept 2014: Both Divisions growing in all regions CHFbn 14 +5% +6% 12 +2% 10 +6% 8 +2% +12% +5% 6 4 2 +7% +3% +3% International Europe +3% Diagnostics Pharma +7% 0 Japan All growth rates at Constant Exchange Rates (CER) US 8 Roche: A pipeline of distinct products Oncology Launched Phase III Phase II 1 Immunology/ Ophthalmology Neuroscience Avastin Rituxan/MabThera Herceptin Xeloda Tarceva Zelboraf Erivedge Perjeta Kadcyla Gazyva/Gazyvaro Esbriet Pulmozyme Xolair Actemra/RoActemra Lucentis Rituxan/MabThera RA pictilisib1 taselisib1 anti-PDL1 BCL2i cobimetinib alectinib lebrikizumab etrolizumab2 lampalizumab3 ocrelizumab gantenerumab 8 phase II 1 phase II 7 phase II Phase III decision pending; 2 FPI in 1H 2014; 3 FPI in 2H 2014 = Respiratory portfolio highlighted 9 Planned data presentations in H2 2014 ASH Berlin, 18-21 Oct mGlu5 • MARIGOLD study (Phase 2 in depression) 1 In collaboration with Chugai Chicago, 30 Oct -1 Nov San Francisco, 6-9 Dec Alecensa (alectinib)1 • Japan Phase 1/2 update Gazyva • GREEN study G + various backbones Avastin Lung • BEYOND study (planned) ACE9101 • Hemophilia 10 2014 Outlook 1 At Group sales growth1 Low- to mid-single digit Core EPS growth1 Ahead of sales growth Dividend outlook Further increase dividend constant exchange rates 11 Pharmaceuticals Division Daniel O’Day COO Roche Pharmaceuticals 12 YTD Sept 2014 sales Innovation Outlook 13 YTD Sept 2014: Pharma sales US and EU remain major growth contributors YTD Sept YTD Sept 2014 2013 Change in % CHFm CHFm 26,965 27,190 -1 4 11,528 11,429 1 5 Europe 7,070 6,952 2 3 Japan 2,406 2,492 -3 7 International 5,961 6,317 -6 3 Pharmaceuticals Division United States CER=Constant Exchange Rates CHF CER 14 YTD Sept 2014: Pharma sales HER2, Avastin & Actemra main growth drivers CER growth Perjeta +255% Herceptin +7% Avastin +6% Kadcyla +148% +24% Actemra/RoActemra MabThera/Rituxan +3% Xolair +24% Activase/TNKase +14% Lucentis +5% Pegasys Xeloda CHFm -17% -43% -600 -400 -200 0 200 Absolute amounts in CHFm at Constant Exchange Rates (CER) average 2013; all growth rates at CER US Europe Japan International 400 600 15 YTD Sept 2014: Oncology sales up 5% CER growth Perjeta HER2 +21%  Strong uptake of Perjeta & Kadcyla +21% Herceptin Kadcyla MabThera/ Rituxan +3% +3% Tarceva 0% 0% Xeloda -43%  In-class competition  Loss of exclusivity in EU (Dec вЂ�13) & US (March вЂ�14)  Competitive pressure in US & EU  Strong growth in International regions -8% -8% Zelboraf CHFbn  Treatment through multiple lines in CRC  Continued uptake in breast cancer (EU) +6% +6% Avastin 0  Increased usage across a variety of indications  Comparison distorted by 340B baseline effect 2 CER=Constant Exchange Rates 4 6 16 Avastin: Future growth supported by ovarian, cervical, breast and colorectal cancer CHFm CER growth Platinum-resistant ovarian cancer 2,000 1,500 +14% +11% +6% • Priority review (FDA, PDUFA Nov 19) and EU approved Cervical cancer • US approved and filed in EU 1,000 HER2 negative breast cancer • Positive Phase 3 data in treatment through multiple lines (TML) and 1L 500 Colorectal cancer 0 Q3 12 US Q3 13 Europe CER=Constant Exchange Rates International Q3 14 • CALGB H2H data support standard of care in 1L Japan 17 HER2 franchise: Strong growth driven by Perjeta and Kadcyla CHFm CER growth +23% 2,000 • ESMO: Unprecedented overall survival benefit in combo with Herceptin of 56.5 months +15% 1,500 Perjeta 1L +16% • US: OS label update expected in Q4 вЂ�14 1,000 Kadcyla 2L • Now approved in 63 countries, UK funding through Cancer Drug Fund 500 Clinical trials 0 Q3 12 Herceptin CER=Constant Exchange Rates Q3 13 Perjeta Q3 14 • MARIANNE results in Q4 вЂ�14 Kadcyla 18 Actemra: Continued uptake SC formulation driving further growth CHFm CER growth 350 +28% 300 250 200 +46% +32% +27% +30% +32% +23% +23% +33% +33% +21% 150 19% SC 81% IV 100 50 0 Q1 12 Q2 12 CER=Constant Exchange Rates Q3 12 Q4 12 Q1 13 Q2 13 Q3 13 Q4 13 Q1 14 Q2 14 Q3 14 19 YTD Sept 2014 sales Innovation Outlook 20 ESMO 2014: Highlights Strong data across the major oncology franchises Metastatic breast cancer Cancer immunotherapy anti-PDL1 • Perjeta: Unprecedented overall survival benefit in 1L HER2+ mBC • Bladder cancer: Strong follow-on data in monotherapy • Renal cancer: Promising early efficacy data in mono & in combo with Avastin • Colorectal cancer : Good safety profile in combo with Avastin & chemo • Avastin: Positive phase 3 data in HER2- mBC in 1L and treatment through multiple lines Melanoma Colorectal cancer • cobimetinib + Zelboraf: Strong profile in a market with rapidly changing treatment options • Avastin: Confirmed standard of care proven survival benefit in 1L & 2L, irrespective of biomarker status 21 CLEOPATRA: Perjeta + Herceptin in 1L mBC Unprecedented overall survival benefit OS analysis: Feb 2014 1.0 0.9 Proportion event-free 0.8 • Unprecedented overall survival benefit of ~5 years despite crossover 0.7 0.6 0.5 HR 0.68 0.4 95% CI = 0.56, 0.84 p = 0.0002 0.3 О” 15.7 0.2 0.1 • MARIANNE still expected by year end (Perjeta + Kadcyla 1L mBC) 40.8 56.5 0.0 0 10 20 30 40 50 60 70 80 Time (months) Perjeta + Herceptin + chemo Placebo + herceptin + chemo Source: Published online in Lancet Oncology Presented at ESMO 2014 22 TANIA: Avastin in 2/3L HER2- mBC Continued use improves outcomes 2L PFS Progression-free survival (%) 100 • Statistically significant improvement in 2L PFS HR 0.75 75 95% CI = 0.61, 0.93 p = 0.0068 50 • No new safety signals 25 • Final OS in 2015 О” 2.1 4.2 6.3 0 0 3 6 9 12 15 18 21 24 27 30 Time (months) Avastin + chemo chemo Source: Published online in Lancet Oncology Presented at ESMO 2014 23 coBRIM: cobimetinib + Zelboraf in melanoma A competitive MEK/BRAF inhibitor combination PFS Progression-free Survival (%) 100 HR 0.51 95% CI = 0.39, 0.68 p < 0.0001 80 • Statistically & clinically significant 60 • Benefits of combination therapy across all relevant subgroups 40 20 • Regulatory status: EU filed, US fast track designation with filing in 2014 О” 3.7 6.2 0 2 4 6 9.9 8 10 12 14 16 Time (months) cobimetinib + Zelboraf (n = 247) Placebo + Zelboraf (n = 248) Source: NEJM 2014 Presented at ESMO 2014 24 Roche in cancer immunotherapy: A comprehensive program in monotherapy and combination Compound Combination Indication PDL1 Mono +Tarceva Lung PDL1 Mono Bladder PDL1 Mono +Avastin Renal PDL1 +Zelboraf Melanoma PDL1 Mono +Avastin +cobimetinib +ipilimumab +IFN alfa-2b Solid tumors PDL1 +Avastin+FOLFOX Colorectal CEA IL-2v Mono +Gazyva Mono +PDL1 +CD40 Mono OX-40 Mono Solid tumors CD-40 Mono Solid tumors PDL1 CSF1R DNA vaccine Mono Hematology Solid tumors Solid tumors Prostate пѓј Study ongoing пѓј Ph 1 Ph 2 Ph 3 пѓј пѓј пѓј пѓј пѓј пѓј пѓј пѓј пѓј пѓј пѓј пѓј пѓј пѓј пѓј пѓј пѓј пѓј пѓј пѓј пѓј пѓј пѓј пѓј пѓј пѓј пѓј Study planned/imminent пѓј 25 Anti-PDL1 in bladder: Confirming strength in cancer immunotherapy PD-L1 IHC (n) ORR (95% CI) IHC 3 (n=10) 60% (27-85) IHC 2 (n=23) 48% (27-68) IHC 1 (n=24) 17% (6-37) IHC 0 (n=12) 8% (0-35) PD-L1 IHC Dx+ vs Dx- ORR (95% CI) 52% (34-69) 14% (6-28) Median PFS (range), weeks Not reached (5 to 48+) 24 (5 to 50+) 11 (0.1+ to 30+) 7 (5 to 24+) Durability of response • 3 complete responses in PD-L1+ • Sustained durability: 19/22 responders continuing to respond • Benign side effect profile • Phase 3 trials planned Anti-PDL1 is listed as MPDL3280A in clinicaltrials.gov. Diagnostic PD-L1-positive: IHC 2 (≥ 5% but < 10% ICs); IHC 3 (≥ 10%. ), PD-L1 negative: IHC 0 (< 1% of ICs) and IHC 1 (≥ 1% but < 5%). 26 Lampalizumab: Pivotal phase 3 started Early AMD Intermediate AMD Advanced AMD Wet AMD Increased drusen & early pigmentary changes • CHROMA & SPECTRI: 2 identical, randomized studies (c.940 pts each) Geographic Atrophy GA is a progressive, irreversible & blinding disorder пЂ Primary endpoint: Reduction in the rate of GA1 disease progression • Phase 2 (MAHALO): Showed high efficacy in subpopulation with exploratory biomarker 1 Geographic Atrophy 27 Esbrietпѓў in the US IPF: Rate of disease progression Actions taken Respiratory function / symptoms US: Change the market from вЂ�watch and wait’ to early diagnosis and treatment Progressive fibrotic disease (slow decline) в€’ Field force trained and in place, logistics ready в€’ Engagement with pulmonologists from existing Xolair franchise Rapid decline в€’ Highlight efficacy and safety profile from day one Episodes of acute respiratory worsening Adapted from Raghu, 1987 1 2 3 Median survival following diagnosis (years) 1 Roman et al 2013; 2 Raghu et al 2011; 3 Nalysnyk et al 2012 4 Ex-US: initiatives to reflect latest clinical data in label в€’ Roche to support ongoing efforts 28 YTD Sept 2014 sales Innovation Outlook 29 Q3 2014 Pipeline update on Phase 3 activity Phase 3 readouts Key Phase 3 starts Compound Indication Compound Indication Kadcyla/Perjeta 1L met. HER2+ BC (MARIANNE) Kadcyla adjuvant BC (KAITLIN) cobimetinib BRAF+ mM (co-BRIM) пѓј Kadcyla Bcl-2 inh anti-PDL1 alectinib etrolizumab gantenerumab lampalizumab Outcome studies are event driven, timelines may change пѓј neo-adjuvant (KRISTINE) пѓј Rel/Ref CLL (MURANO) пѓј 2/3L NSCLC (OAK) пѓј ALK+ NSCLC пѓј inflammatory bowel disease пѓј mild AD (Marguerite RoAD) пѓј geographic atrophy пѓј 30 2014: Key regulatory milestones Compound Indication Milestone Actemra subcutaneous Rheumatoid arthritis EU approval Avastin Glioblastoma EU approval Avastin Cervical cancer US, EU filing Avastin Pt-resistant ovarian cancer EU approval MabThera subcutaneous NHL EU approval Gazyvaro Front line CLL EU approval Xolair Chronic idiopathic urticaria US approval Outcome studies are event driven, timelines may change пѓј пѓ» пѓј пѓј пѓј пѓј пѓј 31 Planned data presentations in H2 2014 ASH Berlin, 18-21 Oct mGlu5 • MARIGOLD study (Phase 2 in depression) 1 In collaboration with Chugai Chicago, 30 Oct -1 Nov San Francisco, 6-9 Dec Alecensa (alectinib)1 • Japan Phase 1/2 update Gazyva • GREEN study G + various backbones Avastin Lung • BEYOND study (planned) ACE9101 • Hemophilia 32 Diagnostics Division Roland Diggelmann COO Roche Diagnostics Picture 33 YTD Sept 2014: Diagnostics sales Growth driven by Professional Diagnostics YTD Sept YTD Sept 2014 2013 Change in % CHFm CHFm 7,792 7,677 1 6 Professional Diagnostics 4,397 4,251 3 8 Diabetes Care 1,721 1,781 -3 1 Molecular Diagnostics 1,165 1,164 0 5 509 481 6 10 Diagnostics Division Tissue Diagnostics 1 Underlying growth of Molecular Diagnostics excluding Sequencing Solutions: +7% CER=Constant Exchange Rates CHF CER 34 YTD Sept 2014: Diagnostics regional sales Growth across all geographies Japan North America +3% +6% EMEA1 25% of divisional sales +3% 4% of divisional sales 46% of divisional sales Latin America +12% 7% of divisional sales Asia Pacific +15% 18% of divisional sales 15% growth in E7 countries1 1 Europe, Middle East and Africa; 2 Brazil, China, India, Mexico, Russia, South Korea, Turkey All growth rates at constant exchange rates 35 YTD Sept 2014: Growth driven by Professional Diagnostics CER growth Professional Dia +8% Diabetes Care 1 Underlying  CE launch of cobas 6800/8800, HPV (+57%), virology (+7%) and blood screening (+5%) +5% Tissue Dia Sales CHFbn  Sales driven by Accu-Chek Aviva/Performa (+6%), Accu-Chek Mobile (+22%) and Insulin Delivery Systems (+5%) +1% Molecular Dia 1 +10% 0 1 2  Continued double digit growth in immunodiagnostics (+12%)  Launch of Anti-MГјllerian Hormone test EMEA North America RoW 3 4  Double digit growth driven by advanced staining portfolio (+8%) and companion diagnostics (+33%) 5 growth of Molecular Diagnostics excluding Sequencing Solutions: +7% CER=Constant Exchange Rates; EMEA=Europe, Middle East and Africa 36 First fully-automated Anti-MГјllerian hormone test for fertility • Expands leading immunoassay portfolio • Target market (IVF): ~ 25 mCHF ; +10% • AMH test superior to FSH, estradiol and ultrasound measurements • Competitive advantages vs manual AMH testing: пЂ High sensitivity пЂ Improved accuracy пЂ At any day of the menstrual cycle пЂ Short time to result • Test is currently also in development as CDx assay Elecsys AMH cobas e411 FSH = follicle-stimulating hormone; rFSH = recombinant follicle-stimulating hormone; IVF = in vitro fertilization; AMH = Anti-MГјllerian hormone 37 RMD: Meet the new family - launches of cobas 6800/8800 High Throughput Reference Labs cobasВ® 8800 • Advanced PCR automation • Highest throughput (3x above closest competitor) • CE launch of blood screening assays; virology assays in Q4 Large Hospitals cobasВ® 6800 • Low to middle volume throughput • Broadest menu incl HPV testing Medium Hospitals cobasВ® 4800 Low Throughput 38 Personalised diabetes management New product launches in 2014 Blood glucose monitoring Diabetes therapy system • Wireless transfer of blood glucose results • Two-way bluetooth communication between pump and remote control • Connect: App with proven bolus advisor • Data synchronization with healthcare professional portal via cloud Accu-Chek Aviva / Performa Connect • Remote control with proven bolus advisor • Discrete and easy handling; intuitive display Accu-Chek Insight 39 Global access program Landmark partnership in HIV with United Nations The program The goals • Special access pricing partnership • UNAIDS target by 2020: пЂ 90% diagnosed пЂ 90% treated пЂ 90% virally suppressed • 40% savings on viral load tests cobas AmpliPrep/cobas TaqMan HIV-1 Test 40 The Ebola outbreak: Roche distributes Ebola PCR Test for research applications LightCycler 480 II • Exclusively distributed by Roche1 on the Lightcycler and cobas platforms • For the presence of the Ebola Zaire virus RNA in biological sample material cobas z 480 1 Developed and produced by TIB MOLBIOL GmbH • Technical evaluation currently underway to prepare for Emergency Use Authorization submission to the US FDA and WHO prequalification 41 Key launches 2014 Instruments / Devices Tests / Assays Area Product Labs cobas 6800/8800 – Next generation molecular (PCR) system cobas m 511 – Fully integrated and automated hematology system cobas 6500 – Automated urinalysis work area platform Connect-V – Middleware providing connectivity to LIS2 Diabetes Care Infectious Diseases / Blood Screening Microbiology Women’s Health *Excluding Accu-Chek Insight- Next generation insulin pump & bGm3 system Accu-Chek Connect – bG meter with connectivity to smart phones, mobile App and cloud MPX 2.0 – Next generation blood screening multiplex test MPX (HIV, HCV, HBV), HEV, DPX4, WNV5 – Full NAT blood screening menu for cobas 6800/8800 HIV, HCV, HBV – Virology tests for cobas 6800/8800 HSV- Detection of Herpes Simplex Virus on cobas 4800 Syphilis– Immunoassay for the detection of Treponema pallidum MRSA/SA – Next generation assay on cobas 4800 C-difficile – Diagnosis of infections and associated diarrhea PE Prognosis- Claim extension for short-term prediction of Preeclampsia in pregnancy AMH- Assessment of ovarion reserve for fertility Market WW* пѓј EU EU пѓј WW RMD RPD RPD RTD EU пѓј RDC EU пѓј RDC US RMD WW* пѓј RMD RMD WW* EU пѓј RMD EU пѓј RPD EU EU EU EU пѓј пѓј RMD RMD пѓј RPD RPD US; Areas: RPD: Roche Professional Diagnostics; RDC: Roche Diabetes Care; RMD: Roche Molecular Diagnostics, RTD: Roche Tissue Diagnostics; 2 hospital information systems; 3 blood glucose monitoring; 4 parvovirus B19 and hepatitis A virus; 5 west nile virus 1 Business BA1 42 Finance Alan Hippe Chief Financial Officer 43 Q3 2014: Highlights Sales and major currency impact • Moderated mainly due to strengthening of US dollar Acquisition of InterMune • Transaction completed • Financing: Bond issuance successfully completed with USD 5.75bn raised 44 Group sales YTD September 2014: Driven by US and Diagnostics +5% +3% +3% +7% +8% +1% Pharma Division +5% 0% +21 +4% +463 +173 +210 Dia Division +176 +1,601 -1,711 +6% +558 -110 United States Europe Intl. Chugai (Japan) Dia Diabetes Care Absolute values in CHFm at CER = Constant Exchange Rates (avg full year 2013); 1 avg December 2013 to avg September 2014 fx Group Fx1 Group CHF 45 Q3 2014: Acquisition of InterMune Update Tender offer and second step merger • Tender offer expired on September 26, 2014 and was not extended – Approx. 79% of InterMune’s outstanding shares were validly tendered on a fully diluted basis • Roche completed acquisition all remaining shares through a second step merger on September 29, 2014 Bond issuance • Bond offering successfully completed on September 22, 2014 • Total of USD 5.75bn raised Impact on outlook • Financial impact expected to be neutral to Core EPS in 2015 and accretive from 2016 • No material impact expected from the transaction in 2014 to sales and core earnings outlook 46 InterMune financing Roche issues USD 5.75 bn of bonds Nominal (USD bn) Treasury yield or Libor (%) Spread bp Roche yield (%) Coupon 1.35 3yr fixed 0.85 1.056 30 1.356 3yr floating 0.30 0.230 9 0.320 5yr fixed 1.50 1.781 50 2.281 5yr floating 0.50 0.230 34 0.570 7yr fixed 1.30 2.249 67 2.919 2.875 10yr fixed 1.30 2.560 82 3.380 3.35 TOTAL 5.75 2.25 2.286 47 Q3 2014: Debt maturity profile 72% of Genentech related debt repaid September 2014 bond issuance (InterMune financing - USD) CHFbn 5 GBP 4 CHF EUR USD 3 2 1 0 2015 2016 2017 2018 2019 2021 2022 2023 2024 2035 2039 Of the CHF 48bn bonds and notes issued to finance the Genentech transaction, cumulative CHF 35bn have been repaid as of September 30, 2014* Nominal values @ actual FX rates; *Original net proceeds in CHF 48 Currency impact on Swiss franc results 2014 Negative currency impact expected CHF / USD Assumed average YTD 2014 Average YTD 2013 0.93 -4% 0.89 +1% 0.90 0.89 0.88 0.88 0.89 Monthly avg fx rates 2014 J F M A M 0.94 0.93 -5% -4% +1% 0.89 0.90 0.90 0.90 0.91 0.94 0.93 -2% 0.91 0.95 Fx rates at 30 September 2014 J J A S O 0.95 0.95 N D Assuming the 30 Sep 2014 exchange rates remain stable until end of 2014, 2014 impact is expected to be (%p): Sales CHF / EUR 1.23 1.22 1.23 1.23 1.23 1.22 -1% -1% 1.22 1.22 -1% +2% 0% +2% 1.23 1.22 1.22 1.22 1.22 1.22 1.22 1.21 1.21 1.21 1.21 1.21 J F M A M J J A S O N D Q1 HY Sep YTD FY -6 -6 -5 -3 Core operating profit -8 -5 Core EPS -8 -5 49 2014 Outlook 1 At Group sales growth1 Low- to mid-single digit Core EPS growth1 Ahead of sales growth Dividend outlook Further increase dividend constant exchange rates 50 Changes to the development pipeline Q3 2014 update New to Phase I New to Phase II New to Phase III 3 NMEs added by gRED RG6046 SERD – ER-pos. HER2neg. mBC (origin Seragon) RG7888 anti-OX40 MAb - solid tumors RG7893 Nav1.7 inhibitor - pain 1NME added by pRED RG6061 HIF1 alpha locked nucleic acid (LNA) - solid tumors (origin Santaris) 1AI RG7446 PD-L1 MAb + ipilimumab or IFN – solid tumors 1AI added following filing go decision RG105 MabThera SC - CLL 1 NME moved from Phase 1 RG7697 GIP/GLP-1 dual agonist T2D 2 NMEs moved from Phase 2 RG7853 alectinib - NSCLC RG7417 lampalizumab - geographic atrophy 1 AI added to reflect the pending FDA submission RG435 Avastin – glioblastoma 1st line Removed from Phase I Removed from Phase II Removed from Phase III 3 NMEs terminated by gRED RG7600 mesothelin ADC pancreatic cancer RG7636 ETBR ADC - metastatic melanoma RG7845 NME - heme tumors Status as of October 16, 2014 1 NME terminated by gRED RG7667 CMV MAb – CMV 1AI RG3616 Erivedge – AML New to Registration 1NME following EU submission RG7421 cobimetinib + Zelboraf metastatic melanoma 1 AI following EU submission RG1273 Perjeta - HER2-pos. BC neoadjuvant 1AI following US submission RG3645 Lucentis – diabetic retinopathy Removed from Registration 1 AI following EU CHMP neg. opinion RG435 Avastin - glioblastoma 1st line 1NME following approval in the EU RG7159 Gazyvaro - CLL 1 AI following approval in the EU RG1569 Actemra - early RA 52 Roche Group development pipeline Phase I (28 NMEs + 10 AIs) Oncology RG105 RG6016 RG6046 RG6061 RG7116 RG7304 RG7388 RG7446 RG7446 RG7446 RG7446 RG7446 MabThera SC CLL LSD1 inh AML SERD ER+(HEr2-) mBC HIF1 alpha LNA solid tumors HER3 MAb solid tumors Raf & MEK dual inh solid tumors MDM2 ant solid & hem tumors PD-L1 MAb+Tarceva NSCLC EGFR+ PD-L1 MAb+Zelboraf m. melanoma PD-L1 MAb+Avastin+chemo solid tumors PD-L1 MAb+cobimetinib solid tumors PD-L1 MAb+ipilimum./IFN solid tumors RG7446 RG7450 RG7458 RG7601 RG7601 RG7666 RG7741 RG7775 RG7813 RG7841 RG7842 RG7882 RG7888 CHU PD-L1 MAb solid tumors Steap 1 ADC prostate ca. MUC16 ADC ovarian & pancreatic ca. Bcl-2 inh + Gazyva CLL Bcl-2 inh heme indications PI3k inh glioblastoma 2L ChK1 inh solid tum & lymphoma MDM2 (4) IV prodrug AML CEA IL2v solid tumors ADC solid tumors ERK inh solid tumors ADC ovarian ca OX40 solid tumors PI3K inh solid tumors Status as of October 16, 2014 Other disease areas RG7624 RG7795 RG7641 CHU RG7203 RG7342 RG7410 RG7893 RG7800 RG7935 RG3645 RG7716 IL-17 MAb autoimmune diseases TLR7 agonist HBV aldosterone synth inh kidney disease URAT 1 inh gout PDE10A inh schizophrenia mGlu5 PAM schizophrenia TAAR1 ago schizophrenia Nav1.7 inh pain SMN2 splicer spinal muscular atrophy a-synuclein MAb Parkinson's Disease Lucentis sust. deliv. AMD/RVO/DME VEGF-ANG2 MAb wAMD New Molecular Entity (NME) Additional Indication (AI) Oncology Immunology Infectious Diseases CardioMetabolism Neuroscience Ophthalmology Other RG-No Roche Genentech managed CHU Chugai managed 53 Roche Group development pipeline Phase II (27 NMEs + 7 Als) RG7155 RG7221 pictilisib RG7321 RG7440 RG7446 RG7446 RG7446 RG7593 RG7596 RG7597 ADC RG7599 RG7601 RG7601 RG7604 RG7686 RG1569 RG3637 RG7449 CHU RG7128 RG7227 RG7745 RG7790 RG7929 RG7697 CSF-1R MAb solid tumors & PVNS Ang2-VEGF MAb colorectal cancer pictilisib (PI3K inh) solid tumors ipatasertib (AKT inh) solid tumors PD-L1 MAb NSCLC 2nd/3rd line PD-L1 MAb + Avastin RCC PD-L1 MAb bladder cancer pinatuzumab vedotin (CD22 ADC) hem tumors polatuzumab vedotin (CD79bADC) hem tumors HER3/EGFR MAb m. epithelial tumors lifastuzumab vedotin (NaPi2bADC)Pt-resist. OC RG1512 RG1577 RG1578 RG1662 RG1678 RG7090 RG7314 RG7412 Bcl-2 inh CLL rel/refract 17pdel Bcl-2 inh DLBCL taselisib (PI3K inh beta sparing) solid tumors glypican-3 MAb liver cancer Actemra systemic sclerosis lebrikizumab idiopathic pulmonary fibrosis quilizumab asthma IL-31R MAb atopic dermatitis mericitabine HCV danoprevir HCV Flu A MAb influenza setrobuvir HCV LptD antibiotic antibacterial GIP/GLP-1 dual ago type 2 diabetes inclacumab ACS/CVD MAO-B inh Alzheimer’s decoglurant (mGlu2 NAM ) depression GABRA5 NAM Down Syndrome bitopertin obsessive compulsive dis. basimglurant (mGlu5 NAM) TRD V1 receptor antag autism crenezumab Alzheimer’s RG6013 FIXa /FX bispecific MAb Status as of October 16, 2014 Registration (1 NMEs + 4 Als) Phase III (9 NMEs + 19 Als) RG4351 Avastin glioblastoma 1st line RG435 Avastin NSCLC adj RG4351 Avastin ovarian cancer 1st line rel. ovarian ca. Pt-sensitive RG4351 Avastin RG1273 Perjeta HER2+ mBC 2nd line RG1273 Perjeta HER2+ BC adj RG1273 Perjeta HER2+ gastric cancer RG3502 Kadcyla HER2+ gastric cancer RG3502 Kadcyla +/- Perjeta HER2+ mBC 1st l RG3502 Kadcyla HER2+ BC adj RG3502 Kadcyla + Perjeta HER2+ BC adj RG3502 Kadcyla + Perjeta HER2+ BC neoadj DLBCL RG7159 Gazyva (obinutuzumab) RG7159 Gazyva (obinutuzumab) iNHL relapsed RG7159 Gazyva (obinutuzumab) iNHL front-line RG7204 Zelboraf melanoma adj RG7446 PD-L1 MAb NSCLC 2nd line RG7601 Bcl-2 inh CLL rel/refract RG7853 alectinib (ALK inhibitor) NSCLC RG1569 Actemra giant cell arteritis severe asthma RG3637 lebrikizumab RG7413 etrolizumab ulcerative colitis CHU Suvenyl enthesopathy CHU IL-6R MAb neuromyelitis optica RG1450 gantenerumab Alzheimer’s RG1594 ocrelizumab RMS RG1594 RG7417 ocrelizumab lampalizumab (factor D) PPMS geo. atrophy RG4352 RG4353 RG12732 RG7421 RG36454 1 2 3 4 Avastin Avastin Perjeta recurrent cervical cancer rel. ovarian ca. Pt-resistant HER2+ BC neoadj cobimetinib + Zelboraf m. melanoma Lucentis diabetic retinopathy US only: FDA submission pending Approved in US, submitted in EU Approved in EU, submitted in US Submitted in US New Molecular Entity (NME) Additional Indication (AI) Oncology Immunology Infectious Diseases CardioMetabolism Neuroscience Ophthalmology Other RG-No Roche Genentech managed CHU Chugai managed RG105 MabThera is branded as Rituxan in US and Japan RG1569 Actemra is branded as RoActemra in EU RG7159 Gazyva is branded as Gazyvaro in EU hemophilia A 54 NME submissions and their additional indications Projects currently in phase 2 and 3 cobimetinib (MEK inh) combo Zelboraf met melanoma пѓј CSF-1R MAb (RG7155) PVNS FIXa /FX bispecific MAb (RG6013) hemophilia A Ang2-VEGF MAb (RG7221) colorectal cancer CRC gantenerumab (RG1450) AlzheimerвЂ�s pictilisib PI3K inh (RG7321) solid tumors MAO-B inh (RG1577) AlzheimerвЂ�s ipatasertib AKT inh (RG7440) solid tumors decoglurant (RG1578) depression idiopathic pulmonary fibrosis pinatuzumab vedotin, RG7593 CD22 ADC heme tumors GABRA5 NAM (RG1662) Down syndrome etrolizumab (RG7413) ulcerative colitis polatuzumab vedotin, RG7596 CD79b ADC heme tumors bitopertin (RG1678) obsessive compulsive dis. quilizumab (RG7449) asthma HER3/EGFR MAb (RG7597) m. epithelial tumors basimglurant (RG7090) depression lampalizumab anti-factor D (RG7417) geo atrophy lifastuzumab RG7599 lebrikizumab (RG3637) lebrikizumab (RG3637) severe asthma NaPi2b ADC Pt resistant OC V1 receptor antag (RG7314) autism mericitabine (RG7128) HCV PDL-1 MAb (RG7446) bladder cancer taselisib PI3K inh ОІ-sparing (RG7604) solid tumors crenezumab (RG7412) AlzheimerвЂ�s danoprevir* (RG7227) HCV PD-L1 MAb (RG7446) NSCLC 2nd/3rd line glypican-3 MAb(RG7686) liver cancer PDL-1 MAb (RG7446) combo Avastin RCC Flu A MAb (RG7745) influenza ocrelizumab (RG1594) PPMS and RMS Bcl-2 inh (RG7601) CLL rel/refract alectinib ALK inh (RG7853) NSCLC Bcl-2 inh (RG7601) DLBCL LptD antibiotic (RG7929) antibacterial 2015 2016 2014 Unless stated otherwise, submissions are planned to occur in US and EU * lead market China Status as of October 16, 2014 2017 and beyond Oncology Immunology Infectious Diseases CardioMetabolism Neuroscience Ophthalmology Other NME 55 Submissions of additional indications for existing products Projects currently in phase 2 and 3 Lucentis (US) diabetic retinopathy пѓј Gazyva iNHL relapsed MabThera SC (EU) CLL **Perjeta (EU) EBC neoadjuvant Gazyva frontline NHL пѓј Zelboraf met. melanoma adj. *Avastin (US) ovarian cancer 1st line *Avastin (US) rel. ovarian ca. Pt-sens пѓј *Avastin (US) rel. ovarian ca. Pt-resist пѓј **Avastin (EU) cervical cancer recurrent 2014 Gazyva DLBCL Avastin (US) glioblastoma 1st line HER2-pos. mBC 2ndline Kadcyla HER2-pos. early BC Kadcyla +/- Perjeta HER2-pos mBC 1st line Perjeta HER2-pos. BC adj Avastin NSCLC adj Kadcyla HER2-pos gastric cancer Actemra giant cell arteritis Actemra systemic sclerosis 2016 2017 and beyond 2015 пѓј Indicates submission to health authorities has occurred. * approved in EU; ** approved in US Unless stated otherwise, submissions are planned to occur in US and EU. Status as of October 16, 2014 Perjeta Perjeta HER2-pos. gastric cancer Oncology Immunology Infectious Diseases CardioMetabolism Neuroscience Ophthalmology Other NME 56 Major granted and pending approvals 2014 Pending approvals Approved Esbriet* idiopathic pulmonary fibrosis October 2014 US EU Japan-Chugai Avastin cervical cancer August 2014 Xolair chronic idiopathic urticaria March 2014 Avastin rel. ovarian ca. Pt-resist Filed May 2014 MabThera NHL sc formulation March 2014 Actemra RA sc formulation April 2014 Avastin cervical cancer Filed April 2014 Gazyvaro CLL July 2014 Actemra early RA September 2014 Perjeta BC neoadjuvant Filed September 2014 Avastin rel. ovarian ca. Pt-resist August 2014 Esbriet* idiopathic pulmonary fibrosis March 2011 cobimetinib + Zelboraf m. melanoma Filed September 2014 alectinib ALECENSA ALK-pos rec/adv NSCLC July 2014 Status as of October 16, 2014; * Newly acquired asset (InterMune) Lucentis diabetic retinopathy Filed August 2014 Zelboraf m. melanoma Filed April 2014 Oncology Immunology Infectious Diseases CardioMetabolism Neuroscience Ophthalmology Other NME 57 Doing now what patients need next
© Copyright 2024 Paperzz
